Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
697 results:
1. A syngeneic spontaneous zebrafish model of
Weiss A; D'Amata C; Pearson BJ; Hayes MN
Elife; 2024 Jul; 13():. PubMed ID: 39052000
[TBL] [Abstract] [Full Text] [Related]
2. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
Tarabini RF; Fioravanti Vieira G; Rigo MM; de Souza APD
Sci Rep; 2024 Jul; 14(1):16721. PubMed ID: 39030304
[TBL] [Abstract] [Full Text] [Related]
3. egfrvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
[TBL] [Abstract] [Full Text] [Related]
4. Revolutionizing Glioblastoma treatment: A Comprehensive Overview of Modern Therapeutic Approaches.
Sadowski K; Jażdżewska A; Kozłowski J; Zacny A; Lorenc T; Olejarz W
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891962
[TBL] [Abstract] [Full Text] [Related]
5. Antipsychotics possess anti-glioblastoma activity by disrupting lysosomal function and inhibiting oncogenic signaling by stabilizing PTEN.
Jacob JR; Palanichamy K; Chakravarti A
Cell Death Dis; 2024 Jun; 15(6):414. PubMed ID: 38871731
[TBL] [Abstract] [Full Text] [Related]
6. CircZNF609 and circNFIX as possible regulators of glioblastoma pathogenesis via miR-145-5p/egfr axis.
Ghadami E; Gorji A; Pour-Rashidi A; Noorbakhsh F; Kabuli M; Razipour M; Choobineh H; Maghsudlu M; Damavandi E; Ghadami M
Sci Rep; 2024 Jun; 14(1):13551. PubMed ID: 38866807
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
Toyoda M; Shibahara I; Shigeeda R; Fujitani K; Tanihata Y; Hyakutake Y; Handa H; Komai H; Sato S; Inukai M; Hide T; Shimoda Y; Kanamori M; Endo H; Saito R; Matsuda KI; Sonoda Y; Kumabe T
J Neurooncol; 2024 Aug; 169(1):39-50. PubMed ID: 38839702
[TBL] [Abstract] [Full Text] [Related]
8. Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the egfr/Integrin β1/FAK signaling pathway.
Zou Y; Xu L; Wang W; Zhu X; Lin J; Li H; Chen J; Xu W; Gao H; Wu X; Yin Z; Wang Q
Phytomedicine; 2024 Jul; 129():155714. PubMed ID: 38723526
[TBL] [Abstract] [Full Text] [Related]
9. Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines.
Stouffer M; Wandling E; Dickson L; Lin S; Duan H; Powe E; Jean-Louis D; Tiwari AK; Amos S
Cancer Rep (Hoboken); 2024 May; 7(5):e2051. PubMed ID: 38702989
[TBL] [Abstract] [Full Text] [Related]
10. A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting egfr in glioblastoma.
Wang F; Zhu Y; Wanggou S; Lin D; Su J; Li X; Tao E
Cancer Lett; 2024 Jun; 592():216920. PubMed ID: 38679408
[TBL] [Abstract] [Full Text] [Related]
11. Exploring ncRNA-mediated regulation of egfr signalling in glioblastoma: From mechanisms to therapeutics.
Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
[TBL] [Abstract] [Full Text] [Related]
12. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
[TBL] [Abstract] [Full Text] [Related]
13. Targeting the egfr pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract] [Full Text] [Related]
14. Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes.
Guyon J; Haidar Ahmad S; El Baba R; Le Quang M; Bikfalvi A; Daubon T; Herbein G
Cancer Gene Ther; 2024 Jul; 31(7):1070-1080. PubMed ID: 38553638
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive mutational scanning of egfr reveals TKI sensitivities of extracellular domain mutants.
Hayes TK; Aquilanti E; Persky NS; Yang X; Kim EE; Brenan L; Goodale AB; Alan D; Sharpe T; Shue RE; Westlake L; Golomb L; Silverman BR; Morris MD; Fisher TR; Beyene E; Li YY; Cherniack AD; Piccioni F; Hicks JK; Chi AS; Cahill DP; Dietrich J; Batchelor TT; Root DE; Johannessen CM; Meyerson M
Nat Commun; 2024 Mar; 15(1):2742. PubMed ID: 38548752
[TBL] [Abstract] [Full Text] [Related]
16. N6-isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity.
Pagano C; Coppola L; Navarra G; Avilia G; Savarese B; Torelli G; Bruzzaniti S; Piemonte E; Galgani M; Laezza C; Bifulco M
FEBS Open Bio; 2024 May; 14(5):843-854. PubMed ID: 38514913
[TBL] [Abstract] [Full Text] [Related]
17. egfr amplification and egfrvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
Neuro Oncol; 2024 Jul; 26(7):1230-1246. PubMed ID: 38507464
[TBL] [Abstract] [Full Text] [Related]
18. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
19. Intrathecal bivalent CAR T cells targeting egfr and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ; Logun M; Fraietta JA; Wang X; Desai AS; Bagley LJ; Nabavizadeh A; Jarocha D; Martins R; Maloney E; Lledo L; Stein C; Marshall A; Leskowitz R; Jadlowsky JK; Christensen S; Oner BS; Plesa G; Brennan A; Gonzalez V; Chen F; Sun Y; Gladney W; Barrett D; Nasrallah MP; Hwang WT; Ming GL; Song H; Siegel DL; June CH; Hexner EO; Binder ZA; O'Rourke DM
Nat Med; 2024 May; 30(5):1320-1329. PubMed ID: 38480922
[TBL] [Abstract] [Full Text] [Related]
20. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
[TBL] [Abstract] [Full Text] [Related]
[Next]
